Noile-Immune Biotech Inc. (4893.T)
JPY 145.0
(0.69%)
JPY 145.0
(0.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -775.39 Million JPY | -629.13% |
| 2022 | - JPY | 86.14% |
| 2021 | - JPY | -35.77% |
| 2020 | -591.67 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -339.28 Million JPY | 0.0% |
| 2024 Q2 | -342.53 Million JPY | -0.87% |
| 2023 Q4 | -279.53 Million JPY | -1846.89% |
| 2023 Q3 | -14.35 Million JPY | 93.23% |
| 2023 FY | - JPY | -629.13% |
| 2023 Q1 | -269.55 Million JPY | -202.18% |
| 2023 Q2 | -211.94 Million JPY | 21.37% |
| 2022 Q4 | 263.81 Million JPY | 0.0% |
| 2022 FY | - JPY | 86.14% |
| 2021 FY | - JPY | -35.77% |
| 2020 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 180.93% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -58.849% |
| GNI Group Ltd. | 14.48 Billion JPY | 105.352% |
| Linical Co., Ltd. | 1.24 Billion JPY | 162.169% |
| Trans Genic Inc. | 240.95 Million JPY | 421.803% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 42.812% |
| Soiken Holdings Inc. | -583.2 Million JPY | -32.953% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -28.569% |
| AnGes, Inc. | -8.86 Billion JPY | 91.248% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 39.681% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 89.52% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 705.268% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 10.152% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 28.979% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1545.25% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 0.026% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -593.546% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 36.01% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 43.846% |
| PeptiDream Inc. | 7.37 Billion JPY | 110.512% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 59.818% |
| Ribomic Inc. | -1.01 Billion JPY | 23.42% |
| SanBio Company Limited | -4.52 Billion JPY | 82.864% |
| Healios K.K. | -3 Billion JPY | 74.214% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 33.488% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 44.339% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 44.694% |
| StemRIM | -2.03 Billion JPY | 61.841% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 159.351% |
| FunPep Company Limited | -952 Million JPY | 18.551% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 12.756% |
| Stella Pharma Corporation | -723.85 Million JPY | -7.12% |
| TMS Co., Ltd. | -937 Million JPY | 17.247% |
| Cuorips Inc. | -518 Million JPY | -49.689% |
| K Pharma,Inc. | 366.05 Million JPY | 311.822% |
| Takara Bio Inc. | 8.02 Billion JPY | 109.663% |
| ReproCELL Incorporated | 8.24 Million JPY | 9504.378% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 981.747% |
| StemCell Institute Inc. | 534.35 Million JPY | 245.108% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 416.727% |
| CellSeed Inc. | -836.51 Million JPY | 7.307% |